Enovis (NYSE:ENOV – Get Rating) and Xylem (NYSE:XYL – Get Rating) are both medical companies, but which is the superior stock? We will contrast the two companies based on the strength of their institutional ownership, dividends, analyst recommendations, profitability, risk, valuation and earnings. Institutional and Insider Ownership 83.8% of Xylem shares are owned by institutional […]
Equities research analysts predict that Enovis Co. (NYSE:ENOV – Get Rating) will post $778.80 million in sales for the current quarter, according to Zacks Investment Research. Three analysts have provided estimates for Enovis’ earnings, with the lowest sales estimate coming in at $368.30 million and the highest estimate coming in at $987.00 million. Enovis posted […]
Wall Street brokerages expect Enovis Co. (NYSE:ENOV – Get Rating) to report $778.80 million in sales for the current fiscal quarter, according to Zacks. Three analysts have made estimates for Enovis’ earnings. The lowest sales estimate is $368.30 million and the highest is $987.00 million. Enovis reported sales of $879.21 million in the same quarter […]
Enovis (NYSE:ENOV – Get Rating) and ITT (NYSE:ITT – Get Rating) are both mid-cap medical companies, but which is the better investment? We will contrast the two companies based on the strength of their profitability, institutional ownership, earnings, risk, analyst recommendations, valuation and dividends. Earnings and Valuation This table compares Enovis and ITT’s gross revenue, […]